Leading the Way in Life Science Technologies

GEN Exclusives

More »

February 1, Vol. 34, No. 3

  • Feature Articles

    • High-Content Analysis: The “Just Right” Solution
    • Kathy Liszewski
    • The ever-expanding field of high-content analysis (HCA) continues to lure scientists from many disciplines Because of its versatility, high-content screening can be used for many applications including basic research, target identification, primary screening, and predicting clinical outcomes CHI’s upcoming “High-Content ... more »
    • In Vivo Imaging Shines
    • Neil McKenna, Ph.D.
    • The discipline of in vivo imaging encompasses a variety of reagents, instruments, and software platforms These tools provide for the noninvasive visual monitoring of processes in living tissues, in both preclinical models and human subjects... more »
    • Cancer Genomics Enters a New Era
    • MaryAnn Labant
    • Vast amounts of genomic discovery research have yet to be translated into routine clinical use In the meantime, scientists continue to advance molecular diagnostics, building evidence to support its use in predicting the best therapeutic approaches... more »
  • Columns

    • miRNA Therapeutics Heading to the Clinic
    • Enal Razvi
    • Currently, there are two segments of the microRNA research marketplace that are translating toward the clinic: miR signatures as biomarkers with utility in diagnostics development and modulating miRs therapeutically as a means to modulate disease... more »
    • AATI Rides the Next-Gen Sequencing Wave
    • Gail Dutton
    • Advanced Analytical Technologies, Inc (AATI) is using the boom in next-generation sequencing and interest from emerging markets to help drive its capillary electrophoresis instrumentation business “Next-gen sequencing for DNA is growing by leaps and bounds in the United States and ... more »
    • Novel Drugs Challenge Anti-TNFs for RA Treatment
    • Gail Dutton
    • Drug developers addressing rheumatoid arthritis (RA) therapeutics are challenging well-established TNF inhibitors with new approaches that promise better efficacy and fewer side effects Leading contenders include multiple JAK inhibitors and interleukin inhibitors, and a potassium channel blocker that has the ... more »